B+
Bull case
20%
Probability
Target price
$20.22
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
NPCE
NeuroPaceBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$16.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+79.7
Score
AI commentary
Recent company and news headlines are directionally positive around FDA approval and the AI roadmap, but the scheduled T+3 earnings follow-up has not produced a verified Q2 operating update, analyst revision signal or attributed price reaction in the available evidence. Low coverage and the missing earnings-specific data warrant monitoring rather than aggressive conviction.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-11eventT+3 earnings follow-up lacks verified Q2 disclosureMedium impact
The scheduled August 6, 2026 earnings follow-up has no verified Q2 release, transcript, guidance update, analyst revision, or attributed market reaction in the available evidence. The last confirmed company earnings source reported Q1 revenue of $22.1 million, RNS revenue growth of 19.5%, and raised full-year revenue guidance to $99-$101 million [#SEC-8K-2026-05-12].
2026-09-30catalystFDA-approved ECoG Assistant creates an AI product hookHigh impact
NeuroPace announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature and the first in a planned suite of AI tools [#IR-2026-05-29]. Commercial adoption and revenue contribution remain unverified.
2027-08-08catalystLosses and financing needs remain an execution overhangHigh impact
The latest verified earnings disclosure showed a $6.7 million GAAP net loss, $54.8 million of cash, cash equivalents, short-term investments and restricted cash, and $59.0 million of long-term borrowings [#SEC-8K-2026-05-12]. A weak Q2 update could renew balance-sheet concerns.
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology